Oncolytic Virus Adaptations for Niche Environments
Legal Citation
Summary of the Inventive Concept
The inventive concept relates to novel oncolytic virus adaptations for treating cancer in specialized environments, including high-altitude, disaster relief, high-security, extreme weather, and limited medical infrastructure settings.
Background and Problem Solved
While the original patent addressed the need for oncolytic viruses with improved safety and anticancer effect, it did not consider the unique challenges and requirements of specific operational environments. The present inventive concept addresses these limitations by adapting the oncolytic virus for optimal efficacy and safety in niche environments.
Detailed Description of the Inventive Concept
The inventive concept involves the design of recombinant oncolytic viruses with nucleotide sequences encoding truncated fragments of HSV1-TK, tailored for specific environments. For example, the virus for high-altitude environments is engineered to maintain efficacy above 8,000 feet, while the virus for disaster relief is designed to resist degradation by environmental stressors. The virus for high-security facilities is engineered to minimize the risk of unauthorized access or tampering, and the virus for extreme weather conditions is adapted for optimal stability and efficacy in temperatures above 100°F or below 0°F. The virus for areas with limited medical infrastructure is designed for ease of administration and minimal equipment requirements.
Novelty and Inventive Step
The new claims introduce novel adaptations of the oncolytic virus for specialized environments, which are not obvious from the original patent. The inventive step lies in the recognition of the need for environment-specific adaptations and the design of the viruses to address these unique challenges.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include adaptations for other niche environments, such as space exploration or remote wilderness areas. Variations of the virus could also be designed for specific types of cancer or patient populations.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the areas of cancer treatment and disaster relief. The target market includes hospitals, research institutions, and government agencies involved in cancer treatment and disaster response.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K35/768 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K31/708 |
| C | C12 | C12N15/86 |
| C | C12 | C12N2710/24111 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and medical virology, specifically oncolytic virus engineering with a focus on genetic modification of viral vectors for cancer therapy. Requires advanced knowledge of molecular biology, genetic engineering, virology, and cancer treatment strategies
Person of Ordinary Skill (PHOSITA) Profile
A PhD-level researcher with expertise in viral vector design, molecular genetics, and cancer therapeutics. Possesses advanced skills in genetic manipulation, understanding of viral protein structures, and ability to modify viral genomes for specific therapeutic purposes
Obviousness Rationale
A PHOSITA would recognize that the environment-specific adaptations of the oncolytic virus represent predictable variations of the source patent's core technology. The fundamental genetic engineering approach of modifying the HSV1-TK fragment remains consistent with the original patent's teachings. The proposed variations represent logical extensions of existing viral engineering techniques applied to specific use contexts.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,585 |
|---|---|
| Title | Oncolytic virus improved in safety and anticancer effect |
| Assignee(s) | BIONOXX INC. |